

1 **SARS-CoV-2 cell entry gene ACE2 expression in immune cells that infiltrate the**  
2 **placenta in infection-associated preterm birth**

3 Phetcharawan Lye<sup>1</sup>, Caroline E. Dunk<sup>2</sup>, Jianhong Zhang<sup>2</sup>, Yanxing Wei<sup>2</sup>, Jittanan  
4 Nakpu<sup>1</sup>, Hirotaka Hamada<sup>1</sup>, Guinever E Imperio<sup>1,2</sup>, Enrrico Bloise<sup>1,3</sup>, Stephen G  
5 Matthews<sup>1,2,4\*\*</sup>, Stephen J Lye<sup>1,2,4\*,\*\*</sup>

6

7 <sup>1</sup>Department of Physiology, University of Toronto, Toronto, Ontario, Canada (P Lye,  
8 H Hamada, GE Imperio, E Bloise, SG Matthews, SJ Lye).

9 <sup>2</sup>Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario,  
10 Canada (J Zhang, Y Wei, J Nakpu, CE Dunk, GE Imperio, SG Matthews, SJ Lye).

11 <sup>3</sup>Department of Morphology, Federal University of Minas Gerais, Belo Horizonte,  
12 Brazil (E Bloise)

13 <sup>4</sup>Department of Obstetrics and Gynecology and Department of Medicine, University  
14 of Toronto, Toronto, Ontario, Canada (SG Matthews, SJ Lye).

15 \*Corresponding author

16 \*\*Contributed equally

17 The authors report no competing interests.

18

19 Correspondence to:

20 Stephen Lye, Lunenfeld-Tanenbaum Research Institute, Sinai Health System,  
21 Toronto, Ontario, Canada.

22 Email: [lye@lunenfeld.ca](mailto:lye@lunenfeld.ca)

23

24 **Abstract**

25 COVID-19 infection during pregnancy is associated with an increased incidence of  
26 preterm birth but neonatal infection is rare. We assessed pathways by which SARS-CoV-  
27 2 could access the placenta and contribute to fetal transmission. Placentas from

28 pregnancies complicated with chorioamnionitis (ChA), exhibited increased expression of  
29 *ACE2* mRNA. Treatment of 2<sup>nd</sup> trimester placental explants with LPS, induced an acute  
30 increase in cytokine expression followed by *ACE2* mRNA. Placental *ACE2* protein  
31 localized to syncytiotrophoblast, in fetal blood vessels and M1/M2 macrophage and  
32 neutrophils within the villous stroma. Increased numbers of M1 macrophage and  
33 neutrophils were present in the placenta of ChA pregnancies. Maternal peripheral  
34 immune cells (mainly granulocytes and monocytes) express the *ACE2* mRNA and  
35 protein. These data suggest that in COVID19 positive pregnancies complicated by ChA,  
36 *ACE2* positive immune cells have the potential to traffic SARS-CoV-2 virus to the placenta  
37 and increase the risk of vertical transmission to the placenta/fetus.

38 Keywords: SARS-CoV-2, COVID-19, *ACE2*, Chorioamnionitis, Preterm birth, M1, M2  
39 macrophages, Monocyte, Neutrophil, LPS, Placenta

40

## 41 **Introduction**

42 A novel coronavirus SARS-CoV-2 (2019-nCoV) appeared in Wuhan, Hubei  
43 Province, China on December 30, 2019, and spread rapidly around the world (Schwartz,  
44 2020). The acute respiratory syndrome caused by SARS-CoV-2 was named Corona Virus  
45 Disease, COVID-19 by the World Health Organization (WHO). At present there are only  
46 a few reports identifying mother to fetus/neonate vertical transmission of COVID-19  
47 infection (Dong *et al.*, 2020). Facchetti et al (2020) recently reported the presence of a  
48 placenta intervillous inflammatory infiltrate consisting of neutrophils and monocyte-  
49 macrophages expressing activation markers in patients with COVID-19 infection, and

50 Chen et al (2020) suggested the potential for transmission of SARS-CoV-2 from an  
51 infected mother to her fetus/neonate before birth. There is limited data on whether SARS-  
52 CoV-2 infections increase the risk of complications in pregnancy (Qiao, 2020). A recent  
53 systematic review meta-analysis of 13 publications related to COVID infection in  
54 pregnancy from China suggests a high rate of maternal and neonatal complications in  
55 infected individuals with a preterm birth rate of 20% and a lower neonatal infection rate of  
56 6% (Capobianco *et al.*, 2020).

57 The immune system is a core component of the maternal-fetal interface. Disruption  
58 of the immune system of a pregnant woman, as in the case of bacterial infection, places  
59 the mother and fetus/neonate at risk of other infections, such as viruses, which can impact  
60 the course of pregnancy for both mother (e.g. preterm birth) (Silasi *et al.*, 2015) and  
61 fetus/neonate (e.g. systemic inflammatory response syndrome) (Francis *et al.*, 2019).  
62 Additionally, it has been suggested that viral infection of the placenta modifies the immune  
63 response to bacterial products by destroying the normal 'tolerance' to LPS and  
64 aggravates the inflammatory response, which in turn leads to preterm labor (Cardenas *et*  
65 *al.*, 2011; Kwon *et al.*, 2014). Immune cells at the maternal-fetal interface play a critical  
66 role in a successful pregnancy. In the first trimester they contribute to remodelling of the  
67 uteroplacental circulation (Hazan 2010; Smith 2009), and at term an influx of maternal  
68 peripheral monocytes into the decidua and myometrium leads to their differentiation into  
69 macrophage which generate inflammatory mediators that contribute to the initiation of  
70 labour (Hamilton *et al.*, 2012; Shynlova *et al.*, 2020). However, these cells also contribute  
71 to pathologies of pregnancy. For example, in cases of acute chorioamnionitis bacterial  
72 infection of the fetal membranes and/or placenta results in an increased influx of maternal

73 neutrophils and monocytes into these tissues where the latter differentiate into classical  
74 activated inflammatory macrophage (Kim *et al.*, 2015; Cappelletti *et al.*, 2020). The  
75 potential adverse consequences to the fetus of placental infection and sensitization to  
76 maternal-fetal viral transmission and the mechanisms by which this might occur require  
77 further investigation.

78 SARS-CoV-2 cell entry is mediated through angiotensin-converting enzyme 2  
79 (ACE2), a protease responsible for the conversion of Angiotensin 1-8 (Ang II) to  
80 Angiotensin 1-7 (Ang 1-7) (Vickers *et al.*, 2002; Jia *et al.*, 2005). Interactions were  
81 identified between the SARS-CoV spike protein and its host receptor ACE2, which  
82 regulate both the cross-species and human-to-human transmission of SARS-CoV (Wan  
83 *et al.*, 2020), and SARS-CoV-2, and share the same receptor, ACE2 (Zhang *et al.*,  
84 2020a). The SARS-CoV spike protein is known to bind ACE2 on the surface of the host  
85 cell via its subunit S1, and then fuse to viral and host membranes through subunit S2.  
86 Viral attachment is facilitated by two domains in subunit S1, which are from different  
87 coronaviruses (Li, 2016). It is currently unknown if SARS-CoV-2 binds in this same  
88 fashion. The expression and distribution of ACE2 has been reported in human fetal heart,  
89 kidneys, liver, lung, and placenta (Crackower *et al.*, 2002; Hamming *et al.*, 2004; Pringle  
90 *et al.*, 2011a). ACE2 mRNA expression has also been found in early gestation placenta  
91 (Pringle *et al.*, 2011a; Bloise *et al.*, 2020). In addition, ACE2 protein levels were found to  
92 be abundant in the syncytiotrophoblast layer (STB) and villous stroma, while less intense  
93 in the trophoblast layer (CTB) (Pringle *et al.*, 2011a). The STB provides the interface  
94 between the maternal blood, containing immune cells, and the extraembryonic tissues  
95 and fetus (Knöfler *et al.*, 2019; Facchetti *et al.*, 2020). Interestingly activated

96 macrophages in patients with heart failure have been shown to express high levels of the  
97 SARS-CoV-2 receptor, *ACE2* (Keidar *et al.*, 2005). Furthermore, in patients with chronic  
98 obstructive pulmonary disease (COPD) activation of neutrophils, NK cells, Th17 cells,  
99 Th2 cells, Th1 cells, dendritic cells, and TNF $\alpha$  secreting cells can be induced by  
100 overexpression of *ACE2* leading to a severe inflammatory response (Li *et al.*, 2020a).  
101 Since these immune cells can potentially engage the SARS-CoV-2 virus, they may also  
102 represent a reservoir for the virus and a vector for the virus to infect the placenta/fetal  
103 membranes in cases of chorioamnionitis.

104 We hypothesize that the presence of an intrauterine bacterial infection will activate  
105 peripheral maternal macrophage and neutrophils and cause them to target the uterus and  
106 intrauterine tissues. If these immune cells express the SARS-CoV-2 cell entry protein,  
107 *ACE2*, then these cells have the potential to transport virus to the placenta and thereby  
108 increase the risk of placental infection and vertical transmission of the virus to the fetus.


109

## 110 **Results**

### 111 **Chorioamnionitis and LPS exposure are associated with increased placental *ACE2*** 112 **expression and an inflammatory cytokine/chemokine response.**

113 Placental *ACE2* mRNA expression was significantly increased ( $P<0.01$ ) in pregnancies  
114 complicated with PTB in the presence of ChA compared with PTB alone or with  
115 uncomplicated spontaneous vaginal delivery (SVD) or not in labour (elective caesarean  
116 section, ELCS) term pregnancies (Figure 1A). Placental mRNA expression of *CCL2* was

117 also significantly increased in ChA ( $P<0.05$ ) compared to all other groups but there was  
118 no significant increase in *IL6/8* mRNA expression (Figure 1C-D).




119

120 **Figure 1. ACE, and chemokine mRNA expression is increased in placenta from preterm labor with**  
121 **chorioamnionitis (ChA).** Bar charts show the relative levels of *ACE2* (A), *CCL2* (B), *IL-6* (C), and *IL-8* (D)  
122 mRNA in placentas from PTB, ChA, SVD and ELCS deliveries, assessed by real time qPCR. Data are  
123 normalized by the geometric mean of *TOP1* and *YWHAZ* (reference genes), N=6-7/group. Statistical  
124 differences were tested by Tukey's multiple comparisons test. Data are presented as mean  $\pm$  SEM. Different  
125 letters indicate a difference between groups of  $p<0.05$ .


126 Treatment of 2<sup>nd</sup> trimester placental explants with LPS (10  $\mu$ g/mL) from elective  
127 terminations of healthy normal pregnancies resulted in a rapid (4 hour) significant

128 increase in placental expression of cytokine (*IL-6/8* and *TNF $\alpha$*  mRNA;  $P<0.05$ ) (Figure  
129 2D-E), as well as higher (but non-significant expression of the chemokine *CCL2* ( $P=0.06$ ))  
130 (Figure 2B). Cytokine/chemokine expression returned to basal levels 24 hours post-LPS  
131 treatment, at which time expression of *ACE2* mRNA in the placental explants increased  
132 significantly ( $p<0.05$ ) (Figure 2A).



134 **Figure 2. Effect of LPS on ACE2, CCL2, IL-6/8 and TNF $\alpha$  mRNA expression in second trimester**  
135 **human placental explants.** Second trimester placental explants were treated with LPS (10  $\mu$ g/mL), or  
136 vehicle for 4 and 24 hours and mRNA levels of ACE2 (A), CCL2 (B), IL-6 (C), IL-8 (D) and TNF $\alpha$  (E), were  
137 quantified by qPCR (n=5/group). Data are normalized by the geometric mean of TOP1 and TBP (reference  
138 genes). Data are expressed as means  $\pm$  SEM. Statistical differences were tested using a paired t-test.  
139 \*p<0.05, versus vehicle.


140 In contrast to the elevated expression of ACE2 mRNA, we did not detect any increase in  
141 ACE2 protein within the placentas of preterm pregnancies associated with ChA, although  
142 the levels of ACE2 protein in preterm placentas (with or without ChA) were significantly  
143 higher (p<0.05) than in placentas at term in the presence or absence of labour (Figure  
144 3B).





146 **Figure 3. Placental ACE2 protein levels are increased in PTB with/without chorioamnionitis (ChA)**  
147 **as compared to term.** Protein lysates of placentas from PTB, ChA, ELCS and SVD deliveries were  
148 assessed for level of ACE2 protein by western blotting. **(A)** Representative western blot images and **(B)**  
149 densitometric analysis of ACE2 protein level, normalized by  $\beta$ -actin (loading control for protein), N =  
150 6/group. Statistical differences were tested by Tukey's multiple comparisons test. Data are presented as  
151 mean  $\pm$  SEM. Different letters if  $p < 0.05$ .

152 Since ACE2 total protein was not increased in ChA placentas, we next determined the  
153 localization of ACE2 protein in the placentas from complicated and uncomplicated  
154 pregnancies. This analysis revealed expression of ACE2 in the syncytiotrophoblast  
155 (STB), which is the fetal tissue in direct connection with maternal blood and in the fetal  
156 blood vessels within the placental villous core. We also observed the presence of ACE2  
157 immunoreactivity in histologically-identified macrophages within the placental villous  
158 stroma and in association with perivascular cells surrounding the fetal blood vessels and  
159 in some fetal blood cells (Figure 4A). ACE2 expression was also present in extravillous  
160 trophoblast (EVT) (Figure 4B) and in decidual stromal cells within the placental basal plate  
161 (Figure 4C), as well as immune cells within maternal blood present in the intervillous  
162 space (Figure 4D).




163

164 **Figure 4. ACE2 localization in the placenta and in maternal intervillous immune cells.**  
165 Representative images of ACE2 immunostaining in a placenta from an uncomplicated PTB delivery (A)  
166 ACE2 staining was localized predominantly in the syncytiotrophoblast layer (STB), fetal blood vessel  
167 (pFECs) and fetal hofbauer cells (MΦ) of the placental villi. (B) ACE2 also localised to extravillous  
168 trophoblast (EVT) within the basal plate of the placenta and in (C) decidua stromal cells. (D) ACE2  
169 expression in maternal neutrophils of maternal blood clot adjacent to the decidua, Sections were counter-  
170 stained with hematoxylin. N=6/group. Scale bar represents 100µm.

171 The finding of ACE2 expression in histologically-identified immune cells within the  
172 placenta led us to undertake further characterization of these cells in placentas from  
173 pregnancies complicated by PTB, in the presence or absence of ChA, as well as term  
174 pregnancies with and without the onset of labour. We used monoclonal antibodies specific

175 for CD68 (which detect the macrophage population); MHC-II - a marker of M1  
176 macrophage; CD206 - a marker of M2 macrophage; and neutrophil elastase (NE) - a  
177 marker of neutrophils. Representative images of immunohistochemical staining revealed  
178 expression of ACE2 was localized to syncytiotrophoblast of all pregnancy groups (Figure  
179 5 A-D) with a reduced intensity of staining in term groups than in preterm groups. ACE2  
180 staining was also apparent in stromal cells which resembled macrophage and neutrophils  
181 (shown in Figure 5 E-T). Staining with CD68 revealed the presence of macrophage within  
182 the placental villous of all pregnancy groups (Figure 5 E-H) and further analysis identified  
183 these to be both M1 (inflammatory) and M2 (angiogenic) sub-types. (Figure 5 I-P). The  
184 M1 macrophage were present throughout the stroma as well as being associated with  
185 fetal blood vessels. Staining with NE detected the presence of neutrophils within the  
186 placental vasculature and villi of all pregnancy groups (Figure 5 Q-T). The distribution of  
187 these immune cells did not appear to be equal across the patient groups, therefore we  
188 sought to quantify their number using Image analysis. Total macrophage numbers were  
189 similar in ChA and PTB control groups however, both of these groups had higher numbers  
190 of macrophage than the term groups (SVD, ELCS; ( $p < 0.01$ ) (Figure 5U). In contrast, the  
191 number of M1 macrophages was significantly increased ( $p < 0.001$ ) in ChA patients  
192 compared to PTB, SVD and ELCS groups (Figure 5V). Whereas, the number of M2 was  
193 significantly higher ( $p < 0.001$ ) in PTB patients compared to ChA, SVD and ELCS groups  
194 (Figure 5W). Quantification of neutrophil numbers across patient groups revealed  
195 significantly higher numbers in ChA pregnancies than in the PTB, SVD or ELCS groups  
196 (Figure 5X;  $p < 0.001$ ).




197

198 **Figure 5. Localization and quantitation of placental ACE2, CD68 (macrophage marker), MHC-II (M1**  
 199 **marker), CD206 (M2 marker) and neutrophil (NE) staining in complicated and uncomplicated**  
 200 **pregnancies.** Representative images of ACE2 (A-D), M1 (MHCII E-H), M2 (CD206 I-L), CD68 (M-P), and  
 201 NE (Q-T) staining in preterm and term placentas (N=6 in each group). Inserts (bottom left) in H mouse IgG1  
 202 and T rabbit IgG1 isotype control staining. Scale bar represents 50µm. Image analysis quantitation of  
 203 positively stained immune cells as a proportion of the total cells number was performed on a randomly  
 204 selected 5% of the total tissue area of each placental section. (U) CD68 (V) M1 (W) M2 (X) NE. Statistical

205 differences were tested by Tukey's multiple comparisons test. Data are presented as mean  $\pm$  SEM. Different  
206 letters represent values significantly  $p < 0.05$ .

207 Next we determined whether ACE2 is localized within infiltrated immune cell populations  
208 in the ChA placenta, by undertaking co-localization immunofluorescence analysis of  
209 ACE2 and CD68 (macrophage), MHC-II (M1), CD206 (M2) and NE (neutrophil) markers.  
210 Co-localization of ACE2 in macrophages (M1 and M2) and neutrophil was detected,  
211 confirming our previous histological findings that infiltrated macrophages within the  
212 placenta express ACE2 and also identifying infiltrating placental neutrophils as  
213 expressing ACE2. Immune cells expressing ACE2 were localized in the villous stroma  
214 and adjacent to fetal blood vessels. Only a subset of each of immune cells expressed  
215 ACE2 (Figure 6 A-L).




216

217 **Figure 6. Co-localization of SARS-CoV-2 associated cell-entry protein, ACE2, within specific**  
218 **immune cell populations in ChA placenta.** Representative images of ACE2, CD68, M1, M2 and NE  
219 staining in immunofluorescence (ACE2; red color and M1, M2, macrophage and NE; green color),  
220 macrophage co-staining with ACE2 (**A-C**) M1 co-staining with ACE2 (**D-F**), M2 co-staining with ACE2 (**G-**  
221 **I**) and neutrophil co-staining with ACE2 (**J-L**). Co-localization of ACE2 and markers of macrophage and  
222 neutrophil confirmed the ACE2 localization within placental macrophages and neutrophils. ACE2  
223 expressing immune cells were present in the villous stroma and adjacent to fetal blood vessels. Only a  
224 subset of each of immune cells expressed ACE2. Arrows show ACE2 staining within CD68, M1, M2 and  
225 NE stained cells. Sections were counter-stained with DAPI (blue color) or co-staining (yellow color). Inserts  
226 (bottom left) in (**C**) mouse and rabbit IgG1 isotype control and (**L**) rabbit IgG1 isotype control staining.  
227 N=3/group. Scale bar represents 12 μm.

228 **Expression of ACE2/ACE2 in circulating maternal immune cells.**

229 Expression of ACE2 mRNA was detected in circulating granulocytes, monocytes and  
230 lymphocytes from pregnant women, though levels were quite variable and were not  
231 significantly different across cell types (Figure 7A). Flow cytometry also revealed that  
232 ACE2 was expressed in fractions of circulating granulocytes, monocytes and neutrophils.  
233 A greater fraction of circulating granulocytes were found to be positive for ACE2 than  
234 lymphocytes, but not monocytes ( $p < 0.05$ ; Figure 7B).



235

236 **Figure 7. The surface expression of ACE2/ACE2 on circulating granulocytes, monocytes and**  
237 **lymphocytes in pregnant women.**

238 **(A)** The relative expression of ACE2 mRNA on granulocytes, monocytes and lymphocytes in maternal  
239 peripheral blood. There are no different between all of group (N=4/group). Statistical differences were tested

240 by Tukey's multiple comparisons test. Data are presented as mean  $\pm$  SEM. **(B)** Peripheral human blood  
241 cells were stained with anti-human ACE2 and CD45 antibodies. The percentage of ACE2+ cells was  
242 calculated according to the gating of viable CD45+ granulocytes, monocytes and lymphocytes. Statistical  
243 analyses were performed by R software (3.4.3). Multiple comparisons were conducted by Kruskal-Wallis  
244 test and Wilcoxon test was followed to examine the statistical difference between two groups. N=6/group.  
245 \*,  $p < 0.05$ .

246

## 247 **Discussion**

248 In this study we provide evidence that under conditions of intrauterine  
249 infection/inflammation there is an influx of ACE2 expressing neutrophils and macrophage  
250 into the placenta. We suggest that this is a potential mechanism by which maternal-fetal  
251 vertical transmission could occur in COVID 19 infected pregnancies.

252 We first demonstrated that *ACE2* mRNA levels were increased in the placenta of  
253 pregnancies complicated by chorioamnionitis compared to placentas from patients of  
254 similar gestational age with no evidence of infection, or from term pregnancies (collected  
255 from non-laboring or laboring deliveries). Despite this increase in mRNA, the expression  
256 of ACE2 total protein levels (measured by WB) was not different in the placenta from  
257 patients with PTB and chorioamnionitis compared to those from PTB without  
258 chorioamnionitis, although both preterm groups expressed higher levels of ACE2 than  
259 placentas from patients at term, in the presence or absence of labour. Previously, it has  
260 been reported that there is minimal expression of ACE2 mRNA in the placenta throughout  
261 pregnancy (Pringle *et al.*, 2011b; Bloise *et al.*, 2020; Li *et al.*, 2020b). However, we  
262 recently demonstrated that placental expression of *ACE2* mRNA is gestational-age  
263 dependent with the highest levels in early pregnancy and low to undetectable levels



264 towards term (Bloise *et al.*, 2020). Our current data suggest a similar gestational-age  
265 dependence pattern for ACE2 protein.

266 We found differences in the cellular distribution of ACE2 in the placenta of patients  
267 with ChA. Immunohistochemical analysis localized ACE2 to the STB layer, which is  
268 exposed to the maternal circulation as well as in the vascular endothelium of the fetal  
269 circulation. Staining was also present in extravillous trophoblast (EVT), and decidual  
270 stromal cells. Our findings are consistent with other studies that ACE2 is highly expressed  
271 in cells at the maternal-fetal interface including, STB, endothelial and perivascular cells  
272 and EVT (Valdés *et al.*, 2006). Acute chorioamnionitis refers to the presence of intra-  
273 amniotic infection or “amniotic fluid infection syndrome” (Romero *et al.*, 1992; Kim *et al.*,  
274 2015). Acute chorioamnionitis can also occur in the absence of demonstrable  
275 microorganisms with “sterile intra-amniotic inflammation”, and is induced by “danger  
276 signals” or DAMPs released under conditions of cellular stress, injury or death (Romero  
277 *et al.*, 1992; Gomez-Lopez *et al.*, 2019). The characteristic histologic and defining  
278 features of acute chorioamnionitis is a diffuse infiltration of neutrophils into the fetal  
279 membranes (Redline *et al.*, 2003; Kim *et al.*, 2015). All of the placentas in the ChA group  
280 were confirmed, by a placental pathologist, to be Grade 1/2, stage 2/3 with fetal  
281 inflammation of the membranes (amnion and chorion) and umbilical cord (Table 1).  
282 Importantly, we noted expression of ACE2 in immune cells within the ChA placenta.  
283 These cells were characterized to be predominantly M1 macrophage and neutrophils,  
284 many of which were found in close association or within the wall of fetal blood vessels.  
285 Quantification of the number of these cells in the placenta from all patient groups  
286 revealed, as expected, significantly greater numbers of these immune cells in

287 pregnancies complicated by acute stage 2/3 ChA than the other pregnancy groups. A  
288 recent study has shown that both maternal and fetal neutrophils are present in the  
289 amnionitic fluid of women with a confirmed intraamniotic infection and/or inflammation  
290 (Gomez-Lopez *et al.*, 2017). We did not confirm that the immune cells within the placental  
291 villi were of maternal or fetal origin in this study. However, we did also observe a maternal  
292 intervillous infiltrate of ACE2 expressing maternal neutrophils and macrophage in the ChA  
293 placenta. Further, mRNA and flow cytometric analysis of ACE2 expression by specific  
294 immune subsets in maternal peripheral blood revealed expression of the SARS CoV-2  
295 cell entry protein in neutrophils, monocytes and lymphocytes, with the fractions of  
296 neutrophils expressing ACE2 being significantly higher than in lymphocytes, but not  
297 monocytes. The surface expression of ACE2 on these peripheral immune cells, provides  
298 a route by which the virus could enter these cells in the peripheral circulation. Since  
299 intrauterine infection (as in the case of chorioamnionitis) leads to activation and targeting  
300 of maternal immune cells (particularly neutrophils and monocytes) to the placenta  
301 (Glauser *et al.*, 1991; Liu *et al.*, 2018), this would provide a direct path which might  
302 facilitate the transmission of viral particles into the placental bed, and subsequently to the  
303 fetus. Thus, maternal immune cells could act as the vector for SARS CoV-2 to infect the  
304 placenta and or fetus.


305 Our data showing that LPS treatment (a model of bacterial infection and  
306 chorioamnionitis) of second trimester placental explants induces a rapid induction of  
307 chemokine/cytokines (*CCL2*, *IL-6/8* and *TNF $\alpha$* ) transcripts and *ACE2* mRNA at 24 hours  
308 provides support that placental bacterial infection might increase the opportunity for  
309 placental infection by SARS CoV-2. Since syncytiotrophoblast and placental resident

310 immune cells express ACE2 two potential routes for viral infection might exist, one  
311 through direct interaction between virus and the outer (syncytial) surface of the placenta  
312 and one through the influx of virus containing immune cells. Moreover, since the activated  
313 immune cells infiltrating into the placenta can release proinflammatory cytokines this  
314 might further enhance placenta ACE2 mRNA expression (Liu *et al.*, 2018). Whether  
315 bacterial LPS can sensitize the placenta to infections by SARS-CoV-2 is not known, and  
316 requires further study.

317         There is conflicting data as to whether SARS-CoV-2 can be transmitted to the fetus  
318 through the placenta in women with COVID-19. Early reports of obstetric and neonatal  
319 outcomes of pregnant women from China with COVID-19 suggested that SARS-CoV-2  
320 infection in pregnancy results in limited neonatal infection (Rasmussen *et al.*, 2020; Zhang  
321 *et al.*, 2020b). However, an increasing number of studies reporting neonatal cases with  
322 congenital or intrapartum infection. So far, 10 infants with SARS-CoV-2 infection meet  
323 these criteria based on a classification system defined by Shah *et al.* (Shah *et al.*, 2020).  
324 Notably, a clinical case report revealed that a neonate born to a COVID-19 infected  
325 pregnant woman was tested positive for SARS-CoV-2 after 36 hours of postnatal life  
326 (Wang *et al.*, 2020), which meets the criteria of intrauterine transmission (Blumberg *et al.*,  
327 2020). In addition, in one preterm pregnancy case, the baby tested negative for COVID-  
328 19 at birth, and positive 24 hours later (Zamaniyan *et al.*, 2020). Three other neonates  
329 showed increased immunoglobulin M (IgM) antibodies specific to COVID19 at birth (Zeng  
330 *et al.*, 2020). There is also a growing body of evidence demonstrating infection of the  
331 placental membrane and the villous trophoblasts, a recent electron microscopy study has  
332 demonstrated the presence of SARS-CoV-2 in placental STB (Algarroba *et al.*, 2020) and

333 Baud et al have reported a case of SARS-CoV-2 positivity in the placental submembranes  
334 and cotyledons together with mixed inflammatory infiltration and funicity in pregnant  
335 woman in the second trimester (Baud *et al.*, 2020). In this case, placental infection of  
336 SARS-CoV-2 was confirmed by the virologic findings from specimen obtaining from the  
337 fetal surface. Previously, various pathways of viral transplacental migration were  
338 concluded based on the studies of Zika virus, including transmission from maternal blood  
339 to EVT, transcytosis via syncytiotrophoblast-expressed receptors, or spreading by  
340 infected maternal immune cells (Chen *et al.*, 2020; Karimi-Zarchi *et al.*, 2020). These data  
341 support our hypothesis of an increased risk of placental and fetal transmission of SARS-  
342 CoV-2 in cases of intrauterine infection/inflammation and chorioamnionitis.

343 In conclusion, our data show that the presence of an intrauterine bacterial infection  
344 results in the infiltration of ACE2 expressing maternal macrophage and neutrophils into  
345 and across the placental tissues (Figure 8). These ACE2 expressing immune cells have  
346 the potential to transport virus to the placenta in cases of COVID-19 infection in pregnancy  
347 and increase the risk of placental infection and vertical transmission of the virus to the  
348 fetus.



349

350 **Figure 8. Schematic model by which maternal immune cells could bring SARS-CoV-2 to the placenta**  
 351 **and increase risk of vertical transmission in pregnancies complicated by intrauterine infection.**

352 Intrauterine bacterial infection, such as occurs in chorioamnionitis (ChA), leads to increased expression  
 353 and release of chemokine/cytokines by the placenta that in turn induce activation of maternal immune cells,  
 354 notably M1 macrophage and neutrophils. These cells then target the sites of infection in the placenta/fetal  
 355 membranes. Subsets of these immune cells express the SARS-CoV-2 cell entry protein, ACE2, and thus  
 356 are targets for viral uptake in women infected with SARS-CoV-2. The virus may then be hypothetically  
 357 transported to the placenta increasing the potential for vertical transmission of the virus to the fetus. MAT=  
 358 maternal blood, FV= fetal vessel, MΦ= M1 macrophage, NE= neutrophil, STB= syncytiotrophoblast, layer  
 359 CT= cytotrophoblast.

360

361

362

363 **Methods**

364

365 **Ethical Approval**

366 This is a cross-sectional study involving placental tissue collection from pregnancies  
 367 (25.3-36.0 weeks' gestation) complicated by preterm birth (PTB; N=12) or preterm birth  
 368 with chorioamnionitis (ChA; N=12) or from term pregnancies (>37 weeks' gestation) from  
 369 healthy women in labour (vaginal delivery, SVD; n=12) or not in labour (elective  
 370 caesarean section, ELCS; N=12). Second trimester human placental tissues were  
 371 collected at 16–20 weeks of pregnancy (N=5/group). All clinical information is depicted in  
 372 Table 1.

373

374 **Table 1.** Clinical profile of placental tissues. BMI, (Body Mass Index); V, (Vaginal), C,  
 375 (Caesarean section with no labor); CL, (Caesarean section with labor); S1, (Stage1); S2,  
 376 (Stage2); S3, (Stage3); Y/N, (Yes/No).

|                                  | <b>PTB</b><br>(N=12)         | <b>ChA</b><br>(N=12)         | <b>ELCS</b><br>(N=12)        | <b>SVD</b><br>(N=12)         |
|----------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
| <b>Maternal Characteristics</b>  |                              |                              |                              |                              |
| Maternal Age (years)             | 29.6 ± 1.83<br>(21-43)       | 28.5 ± 2.25<br>(17-40)       | 35.8 ± 0.85<br>(34-42)       | 32.4 ± 1.06<br>(27-43)       |
| Labor (Y/N)                      | 10:2                         | 11:1                         | 0:12                         | 12:0                         |
| BMI                              | 22.4 ± 1.18<br>(18.26-29.75) | 23.8 ± 1.12<br>(18.30-29.75) | 22.6 ± 1.77<br>(15.24-32.44) | 23.2 ± 1.34<br>(19.08-32.91) |
| <b>Fetal Characteristics</b>     |                              |                              |                              |                              |
| Gestational age (weeks)          | 31.7 ± 0.93<br>(25.3-36.0)   | 29.3 ± 1.01<br>(26-33)       | 38.6 ± 0.30<br>(37-41)       | 39.0 ± 0.32<br>(37-40.4)     |
| Mode of Delivery (V:C:CL)        | 2:1:9                        | 5:1:6                        | 0:12:0                       | 12:0:0                       |
| Neonatal sex (Male/ Female)      | 9:3                          | 8:4                          | 6:6                          | 7:5                          |
| <b>Pathology Characteristics</b> |                              |                              |                              |                              |
| Chorioamnionitis (S1, S2, S3)    | No                           | 1:10:1                       | No                           | No                           |
| Glucocorticoids treatment        | Yes                          | Yes                          | No                           | No                           |

377

378 Human peripheral blood was collected from normal pregnant women at 10-14 weeks of  
 379 pregnancy (N=6). All tissues and peripheral blood were provided by the Research Centre

380 for Women's and Infants' Health Bio Bank program at Sinai Health System and are  
381 collected following informed written consent (process n# 20-0101-E) and in adherence  
382 with the policies of the Sinai Health System and the University of Toronto Research Ethics  
383 Board and in accordance with the Helsinki declaration on the use of human tissues.

384

### 385 **Human Placental Explant Culture**

386 Second trimester human placentae (16 to 20 weeks) from the elective termination of  
387 singleton pregnancies were used to set up the floating explant culture as described earlier  
388 (Lye *et al.*, 2015). Briefly, placental specimens were placed into 1% phosphate-buffered  
389 saline (PBS) with  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  and transported to the laboratory. Tissues were  
390 dissected into villous clusters of approximately 15 to 30 mg, and three villous explants  
391 were cultured per well in 12-well plates that contained Dulbec-co's modified Eagle's  
392 medium/F12, Normocin antibiotic (Invivogen, San Diego, CA), and 1 insulin, transferrin,  
393 and selenium-A (Invitrogen, Grand Island, NY) that was previously equilibrated at 8%  $\text{O}_2$   
394 ( $\text{CO}_2$ , 37 °C) for 24 hours. Explants were cultured for 24 hours and then randomly divided  
395 into treatment groups. Explants were treated with LPS from *Escherichia coli* (10  $\mu\text{g}/\text{mL}$   
396 L4391, Sigma-Aldrich, St. Louis, MO) or vehicle for 4 or 24 hours (Lye *et al.*, 2015).  
397 Explants were then collected and stored at 80°C for total RNA.

### 398 **Immunohistochemistry**

399 Placental tissues (N=5/6group) were processed for immunohistochemical analysis as  
400 previously described (Lye *et al.*, 2019). Briefly, slides were deparaffinized, rehydrated,  
401 and subjected to heat mediated antigen retrieval with 10mM sodium citrate Ph6.0 for

402 CD206 and neutrophil primary antibodies, or 1mM EDTA Ph9.0 for MHC-II, CD68 and  
403 ACE2. After blocking with Dako protein block (Dako, Mississauga, ON, Canada), the  
404 slides were incubated overnight at 4°C with primary antibodies: anti-rabbit ACE2 (1:200,  
405 ab15348, Abcam, Toronto, ON, Canada USA) anti-rabbit MHC-II (M1 marker) (1:400,  
406 ab180779, Abcam), anti-rabbit mannose receptor (CD206 (M2),1:200, ab64693, Abcam),  
407 anti-mouse CD68 (macrophage) (1:100, Dako), anti-rabbit neutrophil (NE)(1:100,  
408 ab21595, abcam) was added instead of the primary antibody. After incubation, the slides  
409 were washed and incubated with the corresponding biotinylated secondary antibody  
410 (1:300, 1 hour, Dako). Sections were washed in 1× PBS (3 × 5 min) and incubated with  
411 streptavidin-HRP (1 h; Dako); immunostaining was detected with the peroxidase  
412 substrate kit DAB (Dako). The slides were counterstained with hematoxylin, dehydrated  
413 in ascending concentrations of ethanol, and cover slipped with mounting medium.  
414 Visualization was undertaken with an Olympus BX61 upright, motorized microscope, and  
415 representative images were captured using an Olympus DP72 digital camera (Olympus,  
416 Tokyo, Japan. Negative controls were performed using either isotype Mouse IgG1 or  
417 rabbit IgG/IgG1 antibodies.

## 418 **Image Analysis and Quantification**

419 Quantification of macrophages subtypes and neutrophils in placental tissues (N=5-  
420 6/group) were performed using an Olympus BX61 microscope equipped with an Olympus  
421 DP72 camera, and the newCAST software (Visopharm). Counts were performed as  
422 previously described (Dunk *et al.*, 2019), using a standard protocol that assigned random  
423 counting frames covering 5% of each total masked tissue area. Brown, positively-staining



424 cells and blue, negatively-staining cells (haematoxylin-stained) were counted at 10X  
425 magnification. A positively stained ratio was generated by dividing the total numbers of  
426 brown, positively-stained cells by the total number of cells counted in the tissue area).

427

## 428 **Double immunofluorescence staining**

429 Different protocols were used for the simultaneous detection of two antigens depending  
430 on the availability of primary antibodies raised in the same or different species. For the  
431 localization of ACE2+CD68 (primary antibodies different species), immunofluorescence  
432 experiments were performed as described previously (Nadeem *et al.*, 2013). In brief, ChA  
433 placental tissue slides were deparaffinized, rehydrated, and subjected to heat mediated  
434 antigen retrieval with 1mM EDTA Ph9. Autofluorescence was reduced using 0.1% Sudan  
435 Black in 70% ethanol (1 minute) and non-specific binding was blocked using 0.1% BSA,  
436 0.3% Triton X-100 and 1% donkey serum in PBS for 1 hour. Placental slides were  
437 incubated with primary antibodies ACE2 (1:100, ab15348, Abcam), anti-mouse CD68  
438 (1:100, Dako), anti-mouse IgG1 (Dako) and anti-rabbit IgG1 (ab171870, Abcam) added  
439 as an isotype control overnight at 4°C. Subsequently, ACE2 + CD68 slides were washed  
440 three times and incubated with fluorescent secondary antibodies, using either the anti-  
441 mouse Alexa 488 (1:1000) or the anti-rabbit Alexa 594 (1:1000) secondary antibodies  
442 (Thermo Fisher Scientific and counterstained with 1 µg/mL of DAPI, for 1 hour).

443 For the localization of ACE2+MHC-II (M1), ACE2+CD206 (M2) and ACE2+Neutrophil  
444 elastase (NE) (primary antibodies the same species), immunofluorescence experiments

445 were performed as described previously (Salio *et al.*, 2005; Dunk *et al.*, 2018; Choudhury  
446 *et al.*, 2019). In brief, ChA placental slides were deparaffinized, rehydrated, and subjected  
447 to antigen retrieval with 1mM EDTA Ph9.0. Autofluorescence was reduced using 0.1%  
448 Sudan Black in 70% ethanol (1 minutes) and non-specific binding was blocked using 0.1%  
449 BSA, 0.3% Triton X-100 and 1% donkey serum in PBS for 1 hour. Placental tissues slides  
450 were incubated with primary antibodies ACE2 (1:100, ab15348, Abcam) overnight at 4°C.  
451 Subsequently, ACE2 slides were washed three times and incubated with fluorescent  
452 secondary antibodies using anti-rabbit Alexa 594 (1:1000) (Thermo Fisher Scientific for 1  
453 hour). Slides were washed three times and blocked with 0.1% BSA, 0.3% Triton X-100  
454 and 5% goat serum in PBS for 1 h. Slides were incubated with primary antibodies anti  
455 rabbit-MHC II (M1) (1:100, Abcam), anti-rabbit mannose receptor (CD206, M2,1:100,  
456 Abcam) anti-rabbit NE (1:100, Abcam) and anti-rabbit IgG1 (Abcam) added as an isotype  
457 control overnight at 4°C. Slides were incubated with the corresponding biotinylated  
458 secondary antibody (1:300, 1 h, Dako) then washed three times and incubated with  
459 Streptavidin-Alexa488 (1:2000, Thermo Fisher Scientific and nuclei were stained with 1  
460 µg/mL of DAPI, for 1 h). All slides from the primary antibodies as the same or different  
461 species were washed three times. Fluorescent microscopy was performed using a  
462 spinning disc confocal microscope at various magnifications.

### 463 **Quantitative Real Time PCR (qPCR)**

464 Total RNA was isolated from flash frozen, stored in -80C placental specimens using  
465 the RNeasy Plus Universal Mini Kit (73404, Qiagen, Toronto, ON, Canada), as previously  
466 described (Lye *et al.*, 2019). RNA concentration and purity were assessed using a

467 NanoDrop1000 Spectrophotometer (Thermo Scientific). RNA was reverse transcribed  
 468 into cDNA using the iScript Reverse Transcription Supermix (Bio-Rad). *ACE2*, *IL-6*, *IL-8*,  
 469 *TNF $\alpha$*  and *CCL2* mRNA levels were measured by qPCR using SYBR Green reagent  
 470 (Sigma-Aldrich) and the CFX 380 Real-Time system C1000 TM Thermal Cycler (Bio-  
 471 Rad), with the following cycling conditions: initial denaturation at 95 °C (2 min) followed  
 472 by 39 cycles of denaturation at 95 °C (5 s) and combined annealing and extension at 60  
 473 °C (20 s). Gene expression was normalized to the geometric mean of selected reference  
 474 genes, including DNA topoisomerase 1 (*TOP1*) and the zeta polypeptide (*YWHAZ*) which  
 475 had stable expression across pregnancies complicated by PTB or ChA or from SVD or  
 476 ELCS groups. *TOP1* and TATA-box binding protein (*TBP*) were used in studies of LPS  
 477 treatments in second trimester explants. The relative expression of target genes was  
 478 calculated by the 2- $\Delta\Delta$ CT method (Livak & Schmittgen, 2001). The primer sequences of  
 479 all the assessed genes are shown in Table 2.  
 480

**Table 2.** List of primers used in this study.

| Primer name                   | Sequence                                    | Reference                     |
|-------------------------------|---|-------------------------------|
| <i>ACE2</i>                   | Forward: 5'- GGAGTGATAGTGGTTGGCATTGTC -3'   | *                             |
|                               | Reverse: 5'-GCTAATATCGATGGAGGCATAAGGA-3'    |                               |
| <i>IL-6</i>                   | Forward: 5'-TGCAGAAAAAGGCAAAGAAT-3'         | (Lye <i>et al.</i> , 2019)    |
|                               | Reverse: 5'-CTGACCAGAAGAAGGAATGC-3'         |                               |
| <i>IL-8</i>                   | Forward: 5'-TGGGAACAAGAGGGCATCTG-3'         | (Lye <i>et al.</i> , 2019)    |
|                               | Reverse: 5'-CCACCACTGCATCAAATTCATG-3'       |                               |
| <i>CCL2</i>                   | Forward: 5'-TTCATTCCCCAAGGGCTCGCTCA -3'     | (Lye <i>et al.</i> , 2015)    |
|                               | Reverse: 5'-AGCACAGATCTCCTTGGCCACAA -3'     |                               |
| <i>TNF<math>\alpha</math></i> | Forward: 5'-CCTGGGGAAGTCTTCCCTCTGGGG -3'    | *                             |
|                               | Reverse: 5'-CAGGCGCCACCACGCTCTTC -3'        |                               |
| <i>TBP</i>                    | Forward: 5'-TGC ACA GGA GCC AAG AGT GAA -3' | (Keidar <i>et al.</i> , 2005) |
|                               | Reverse: 5'-CAC ATC ACA GCT CCC CAC CA -3'  |                               |
| <i>YWHAZ</i>                  | Forward: 5'-CCGCCAGGACAAACCAGTAT-3'         | (Drewlo <i>et al.</i> , 2012) |

Reverse: 5'-CAC ATC ACA GCT CCC CAC CA-3'  
*TOP1* Forward: 5'-GATGAACCTGAAGATGATGGC-3' (Drewlo *et al.*, 2012)  
Reverse: 5'-TCAGCATCATCCTCATCTCG-3'

---

\*Gene specific primers were designed with Primer-BLAST (<http://www.ncbi.nlm.nih.gov/tools/primer-blast>).

481

## 482 Immunoblotting

483 Western blot analysis was conducted as previously described (Lye *et al.*, 2019) Briefly,  
484 protein isolated from cultured cells was extracted by sonication using lysis buffer (1 mol/L  
485 Tris-HCL pH 6.8, 2% SDS, 10% glycerol with added protease and phosphatase inhibitor  
486 cocktail; Thermo Scientific). The protein concentration was determined with the Pierce  
487 BCA Protein Assay kit (Thermo Scientific). Proteins were separated by electrophoresis  
488 (30 µg 100 V, 1 h) using SDS polyacrylamide gels (8%). Proteins were then transferred  
489 (10 min) to polyvinylidene fluoride (PVDF) membrane using Trans-Blot Turbo (Bio-Rad).  
490 Membranes were blocked with skim milk (5%; 1 h at room temperature). The primary  
491 antibodies used were anti-rabbit ACE2 (dilution 1:1000; Abcam, ab108209, Toronto, ON,  
492 Canada) and anti-goat  $\beta$ -actin (dilution 1:2000; Santa Cruz Biotechnology, Dallas, TX,  
493 USA). Blots were incubated with primary antibodies overnight at 4 °C. The PVDF  
494 membranes were subsequently incubated for 1 h with HRP-linked anti-goat secondary  
495 antibody (GE Healthcare Bio-Science, Baie d'Urfe, QC, Canada) at concentrations of  
496 1:10,000. Protein-antibody complexes were detected by incubating (for 5 min) the PVDF  
497 membranes with Laminate Crescendo Western HRP Substrate (Millipore, Oak Drive, CA,  
498 USA) and chemiluminescence was detected under UV by using the ChemiDoc<sup>TM</sup> MP

499 Imaging system (Bio-Rad). The protein band intensity was quantified using Image Lab™  
500 software.

### 501 **Immune cell isolation**

502 Peripheral blood samples were collected prospectively into EDTA blood collection tubes  
503 from pregnant women in the first trimester (10-14 gestational weeks) during the regular  
504 antenatal visit. Monocytes and lymphocytes were isolated separately using the  
505 RosetteSep Human Total Lymphocyte Enrichment Cocktail and the RosetteSep Human  
506 Total Lymphocyte Enrichment Cocktail (both from Stemcell Technologies, BC, CA)  
507 following manufacturer's instructions as described earlier (Paquette *et al.*, 2018).  
508 RosetteSep technology uses high-density gradient centrifugation to generate a highly  
509 purified and stable leukocyte fraction RNA expression studies. Following isolation, the  
510 monocytes and lymphocytes were re-suspended in RPMI-1640 with 10% FBS. Primary  
511 human neutrophils were isolated by Histopaque double density gradient method,  
512 consisting of HISTOPAQUE®-1119 and HISTOPAQUE®-1077 (Sigma-Aldrich, MO,  
513 USA). Neutrophils were collected, washed twice in HBSS+ and spun again (Amsalem *et*  
514 *al.*, 2014).

### 515 **Flow cytometry**

516 Direct immunofluorescence staining was performed using peripheral blood collected from  
517 pregnant women at 10-14 weeks of pregnancy. In brief, the whole blood (50µl) was  
518 stained with LIVE/DEAD® fixable cell stain kit (L/D-violet; Invitrogen) and then incubated  
519 with human Fc block (BD Pharmingen) and incubated for 30 minutes. To detect the  
520 expression of ACE2 protein, surface staining was conducted by Alexa Fluor® 700-

521 conjugated mouse anti-human ACE-2 (R&D Systems) and APC-H7 mouse anti-human  
522 CD45 (BD Biosciences) antibodies. Cells were washed and resuspended in stabilizing  
523 fixative buffer (BD Biosciences) to preserve immunofluorescence staining signals of  
524 human blood.

525 Flow cytometric data were acquired with a Gallios flow cytometer (Beckman Coulter).  
526 Data analyses were performed by FlowJo V10 (TreeStar) or Kaluza 2 (Beckman Coulter)  
527 software. Only viable CD45+ blood cells were analyzed for their ACE2 expression.  
528 Circulating lymphocytes, monocytes and granulocytes were recognized by their distinct  
529 morphological features in the forward and side scatter distribution.

### 530 **Statistical Analysis**

531 All analyses were conducted blind to the experimental conditions. Data analyses  
532 were performed with Prism version 8 (GraphPad Software Inc., San Diego, CA, USA)  
533 qPCR data were assessed for normal distribution using D'Agostino and Pearson or the  
534 Shapiro-Wilk test; outliers were identified using "QuickCalcs" Outlier calculator program  
535 (version 7.0; GraphPad Software, Inc., San Diego, CA). Gene and protein expression,  
536 number of macrophages, and maternal immune cell were analyzed using one-way  
537 ANOVA followed by Tukey's multiple comparisons test. Results from LPS-treated  
538 explants were assessed by paired *t*-test. Gene expression of the LPS treated explants  
539 were normalized to their respected vehicle group at both 4 and 24 hours. Differences  
540 were considered statistically significant when  $p < 0.05$ .

541

542

543 **Author Contributions**

544 Conceptualization: PL, CED, SGM, SJL; Funding acquisition: SJL, SGM;

545 Methodology: PL, CED, JZ, JN, GEI, SL; Project administration SGM, SJL; Supervision:

546 SGM, SJL; Validation: PL, CED, JZ; Writing - original draft: PL, CED, HH, EB, JZ, YW;

547 Writing - review & editing: CED, PL, HH, JN, YW, GEI, EB, SGM, SJL.

548

549 **Acknowledgement**

550 The authors thank the donors, RCWIH BioBank, the Lunenfeld-Tanenbaum Research  
551 Institute, and the Mount Sinai Hospital/UHN Department of Obstetrics and Gynaecology  
552 for the human specimens used in this study (<http://biobank.lunenfeld.ca>). We are grateful  
553 for the assistance provided by Mrs. Anna Dorogin in optimising immunostaining, Mrs.  
554 Elzbieta Matysiak-Zablocki with the isolation of granulocytes, monocytes and  
555 lymphocytes and Dr. Oksana Shynlova with the isolation of maternal immune cell  
556 protocols.

557 **Additional Information**

558 The authors report no conflict of interest.

559 E.B. is supported by the Coordenação de Aperfeiçoamento Pessoal de Nível Superior  
560 [CAPES]; finance code 001, CAPES-Print fellowship). S.J.L. is supported by a grant  
561 (FDN-143262) from the Canadian Institutes of Health Research (CIHR). S.G.M. is  
562 supported by a grant (FDN-148368) from the CIHR.

563 The funders had no role in the experimental design, data acquisition, analysis, and  
564 interpretation or in the manuscript writing and conception of this study. The corresponding  
565 authors had full access to all the data in the study and had final responsibility for the  
566 decision to submit for publication.

567

## 568 **Additional Information**

569 Available from the authors upon reasonable request

570

571

## 572 **References**

- 573 Algarroba, G.N., Rekawek, P., Vahanian, S.A., Khullar, P., Palaia, T., Peltier, M.R., Chavez,  
574 M.R. & Vintzileos, A.M. (2020) Visualization of SARS-CoV-2 virus invading the human  
575 placenta using electron microscopy. *American journal of obstetrics and gynecology*.  
576
- 577 Amsalem, H., Kwan, M., Hazan, A., Zhang, J., Jones, R.L., Whittle, W., Kingdom, J.C., Croy,  
578 B.A., Lye, S.J. & Dunk, C.E. (2014) Identification of a novel neutrophil population:  
579 proangiogenic granulocytes in second-trimester human decidua. *Journal of immunology*  
580 *(Baltimore, Md. : 1950)*, **193**, 3070-3079.  
581
- 582 Baud, D., Greub, G., Favre, G., Gengler, C., Jaton, K., Dubruc, E. & Pomar, L. (2020) Second-  
583 Trimester Miscarriage in a Pregnant Woman With SARS-CoV-2 Infection. *Jama*, **323**,  
584 2198-2200.  
585
- 586 Bloise, E., Zhang, J., Nakpu, J., Hamada, H., Dunk, C.E., Li, S., Imperio, G.E., Nadeem, L.,  
587 Kibschull, M., Lye, P., Matthews, S.G. & Lye, S.J. (2020) Expression of severe acute  
588 respiratory syndrome coronavirus 2 cell entry genes, angiotensin-converting enzyme 2  
589 and transmembrane protease serine 2, in the placenta across gestation and at the maternal-  
590 fetal interface in pregnancies complicated by preterm birth or preeclampsia. *American*  
591 *journal of obstetrics and gynecology*. S0002-9378(20)30884-X.  
592
- 593 Blumberg, D.A., Underwood, M.A., Hedriana, H.L. & Lakshminrusimha, S. (2020) Vertical  
594 Transmission of SARS-CoV-2: What is the Optimal Definition? *American journal of*  
595 *perinatology*, **37**, 769-772.  
596



- 597 Capobianco, G., Saderi, L., Aliberti, S., Mondoni, M., Piana, A., Dessole, F., Dessole, M.,  
598 Cherchi, P.L., Dessole, S. & Sotgiu, G. (2020) COVID-19 in pregnant women: A  
599 systematic review and meta-analysis. *European journal of obstetrics, gynecology, and*  
600 *reproductive biology*, **252**, 543-558.
- 601  
602 Cappelletti, M., Presicce, P. & Kallapur, S.G. (2020) Immunobiology of Acute  
603 Chorioamnionitis. *Front Immunol*, **11**, 649-649.
- 604  
605 Cardenas, I., Mor, G., Aldo, P., Lang, S.M., Stabach, P., Sharp, A., Romero, R., Mazaki-Tovi, S.,  
606 Gervasi, M. & Means, R.E. (2011) Placental viral infection sensitizes to endotoxin-  
607 induced pre-term labor: a double hit hypothesis. *American journal of reproductive*  
608 *immunology (New York, N.Y. : 1989)*, **65**, 110-117.
- 609  
610 Chen, H., Guo, J., Wang, C., Luo, F., Yu, X., Zhang, W., Li, J., Zhao, D., Xu, D., Gong, Q.,  
611 Liao, J., Yang, H., Hou, W. & Zhang, Y. (2020) Clinical characteristics and intrauterine  
612 vertical transmission potential of COVID-19 infection in nine pregnant women: a  
613 retrospective review of medical records. *Lancet (London, England)*, **395**, 809-815.
- 614  
615 Choudhury, R.H., Dunk, C.E., Lye, S.J., Harris, L.K., Aplin, J.D. & Jones, R.L. (2019) Decidual  
616 leucocytes infiltrating human spiral arterioles are rich source of matrix metalloproteinases  
617 and degrade extracellular matrix in vitro and in situ. *American journal of reproductive*  
618 *immunology (New York, N.Y. : 1989)*, **81**, e13054.
- 619  
620 Crackower, M., Sarao, R., Oudit, G., Yagil, C., Kozieradzki, I., Scanga, S., Oliveira-dos-Santos,  
621 A., Costa, J., Zhang, L., Pei, Y., Scholey, J., Ferrario, C., Manoukian, A., Chappell, M.,  
622 Backx, P., Yagil, Y. & Penninger, J. (2002) Angiotensin-converting enzyme 2 is an  
623 essential regulator of heart function. *Nature*, **417**, 822-828.
- 624  
625 Dong, L., Tian, J., He, S., Zhu, C., Wang, J., Liu, C. & Yang, J. (2020) Possible Vertical  
626 Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn. *Jama*, **323**,  
627 1846-1848.
- 628  
629 Drewlo, S., Levytska, K. & Kingdom, J. (2012) Revisiting the housekeeping genes of human  
630 placental development and insufficiency syndromes. *Placenta*, **33**, 952-954.
- 631  
632 Dunk, C., Kwan, M., Hazan, A., Walker, S., Wright, J.K., Harris, L.K., Jones, R.L., Keating, S.,  
633 Kingdom, J.C.P., Whittle, W., Maxwell, C. & Lye, S.J. (2019) Failure of Decidualization  
634 and Maternal Immune Tolerance Underlies Uterovascular Resistance in Intra Uterine  
635 Growth Restriction. *Frontiers in Endocrinology*, **10**.
- 636  
637 Dunk, C.E., Pappas, J.J., Lye, P., Kibschull, M., Javam, M., Bloise, E., Lye, S.J., Szyf, M. &  
638 Matthews, S.G. (2018) P-Glycoprotein (P-gp)/ABCB1 plays a functional role in  
639 extravillous trophoblast (EVT) invasion and is decreased in the pre-eclamptic placenta.  
640 *Journal of cellular and molecular medicine*, **22**, 5378-5393.
- 641

- 642 Facchetti, F., Bugatti, M., Drera, E., Tripodo, C., Sartori, E., Cancila, V., Papaccio, M.,  
643 Castellani, R., Casola, S., Boniotti, M.B., Cavadini, P. & Lavazza, A. (2020) SARS-  
644 CoV2 vertical transmission with adverse effects on the newborn revealed through  
645 integrated immunohistochemical, electron microscopy and molecular analyses of  
646 Placenta. *EBioMedicine*, **59**, 102951.  
647
- 648 Francis, F., Bhat, V., Mondal, N., Adhisivam, B., Jacob, S., Dorairajan, G. & Harish, B.N.  
649 (2019) Fetal inflammatory response syndrome (FIRS) and outcome of preterm neonates -  
650 a prospective analytical study. *The journal of maternal-fetal & neonatal medicine : the*  
651 *official journal of the European Association of Perinatal Medicine, the Federation of*  
652 *Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*, **32**,  
653 488-492.  
654
- 655 Glauser, M.P., Zanetti, G., Baumgartner, J.D. & Cohen, J. (1991) Septic shock: pathogenesis.  
656 *Lancet (London, England)*, **338**, 732-736.  
657
- 658 Gomez-Lopez, N., Romero, R., Maymon, E., Kusanovic, J.P., Panaitescu, B., Miller, D., Pacora,  
659 P., Tarca, A.L., Motomura, K., Erez, O., Jung, E., Hassan, S.S. & Hsu, C.D. (2019)  
660 Clinical chorioamnionitis at term IX: in vivo evidence of intra-amniotic inflammasome  
661 activation. *Journal of perinatal medicine*, **47**, 276-287.  
662
- 663 Gomez-Lopez, N., Romero, R., Xu, Y., Leng, Y., Garcia-Flores, V., Miller, D., Jacques, S.M.,  
664 Hassan, S.S., Faro, J., Alsamsam, A., Alhousseini, A., Gomez-Roberts, H., Panaitescu,  
665 B., Yeo, L. & Maymon, E. (2017) Are amniotic fluid neutrophils in women with  
666 intraamniotic infection and/or inflammation of fetal or maternal origin? *American journal*  
667 *of obstetrics and gynecology*, **217**, 693.e691-693.e616.  
668
- 669 Hamilton, S., Oomomian, Y., Stephen, G., Shynlova, O., Tower, C.L., Garrod, A., Lye, S.J. &  
670 Jones, R.L. (2012) Macrophages infiltrate the human and rat decidua during term and  
671 preterm labor: evidence that decidual inflammation precedes labor. *Biology of*  
672 *reproduction*, **86**, 39.  
673
- 674 Hamming, I., Timens, W., Bulthuis, M.L.C., Lely, A.T., Navis, G.J. & van Goor, H. (2004)  
675 Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A  
676 first step in understanding SARS pathogenesis. *J Pathol*, **203**, 631-637.  
677
- 678 Jia, H.P., Look, D.C., Shi, L., Hickey, M., Pewe, L., Netland, J., Farzan, M., Wohlford-Lenane,  
679 C., Perlman, S. & McCray, P.B., Jr. (2005) ACE2 receptor expression and severe acute  
680 respiratory syndrome coronavirus infection depend on differentiation of human airway  
681 epithelia. *J Virol*, **79**, 14614-14621.  
682
- 683 Karimi-Zarchi, M., Neamatzadeh, H., Dastgheib, S.A., Abbasi, H., Mirjalili, S.R., Behforouz, A.,  
684 Ferdosian, F. & Bahrami, R. (2020) Vertical Transmission of Coronavirus Disease 19  
685 (COVID-19) from Infected Pregnant Mothers to Neonates: A Review. *Fetal and*  
686 *pediatric pathology*, **39**, 246-250.  
687

- 688 Keidar, S., Gamliel-Lazarovich, A., Kaplan, M., Pavlotzky, E., Hamoud, S., Hayek, T., Karry, R.  
689 & Abassi, Z. (2005) Mineralocorticoid receptor blocker increases angiotensin-converting  
690 enzyme 2 activity in congestive heart failure patients. *Circulation research*, **97**, 946-953.  
691
- 692 Kim, C.J., Romero, R., Chaemsaitong, P., Chaiyasit, N., Yoon, B.H. & Kim, Y.M. (2015)  
693 Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical  
694 significance. *American journal of obstetrics and gynecology*, **213**, S29-52.  
695
- 696 Knöfler, M., Haider, S., Saleh, L., Pollheimer, J., Gamage, T. & James, J. (2019) Human  
697 placenta and trophoblast development: key molecular mechanisms and model systems.  
698 *Cellular and molecular life sciences : CMLS*, **76**, 3479-3496.  
699
- 700 Kwon, J.Y., Romero, R. & Mor, G. (2014) New insights into the relationship between viral  
701 infection and pregnancy complications. *American journal of reproductive immunology*  
702 (*New York, N.Y. : 1989*), **71**, 387-390.  
703
- 704 Li, F. (2016) Structure, Function, and Evolution of Coronavirus Spike Proteins. *Annual review of*  
705 *virology*, **3**, 237-261.  
706
- 707 Li, G., He, X., Zhang, L., Ran, Q., Wang, J., Xiong, A., Wu, D., Chen, F., Sun, J. & Chang, C.  
708 (2020a) Assessing ACE2 expression patterns in lung tissues in the pathogenesis of  
709 COVID-19. *J Autoimmun*, **112**, 102463-102463.  
710
- 711 Li, M., Chen, L., Zhang, J., Xiong, C. & Li, X. (2020b) The SARS-CoV-2 receptor ACE2  
712 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study.  
713 *PloS one*, **15**, e0230295.  
714
- 715 Liu, X., Yin, S., Chen, Y., Wu, Y., Zheng, W., Dong, H., Bai, Y., Qin, Y., Li, J., Feng, S. &  
716 Zhao, P. (2018) LPS-induced proinflammatory cytokine expression in human airway  
717 epithelial cells and macrophages via NF- $\kappa$ B, STAT3 or AP-1 activation. *Molecular*  
718 *medicine reports*, **17**, 5484-5491.  
719
- 720 Livak, K.J. & Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time  
721 quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods (San Diego, Calif.)*, **25**,  
722 402-408.  
723
- 724 Lye, P., Bloise, E., Javam, M., Gibb, W., Lye, S.J. & Matthews, S.G. (2015) Impact of bacterial  
725 and viral challenge on multidrug resistance in first- and third-trimester human placenta.  
726 *The American journal of pathology*, **185**, 1666-1675.  
727
- 728 Lye, P., Bloise, E., Nadeem, L., Peng, C., Gibb, W., Ortiga-Carvalho, T.M., Lye, S.J. &  
729 Matthews, S.G. (2019) Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibits Extra  
730 Villous Trophoblast Migration: The Impact of Bacterial and Viral Infection. *Cells*, **8**.  
731

- 732 Nadeem, L., Brkic, J., Chen, Y.F., Bui, T., Munir, S. & Peng, C. (2013) Cytoplasmic  
733 mislocalization of p27 and CDK2 mediates the anti-migratory and anti-proliferative  
734 effects of Nodal in human trophoblast cells. *Journal of cell science*, **126**, 445-453.  
735
- 736 Paquette, A.G., Shynlova, O., Kibschull, M., Price, N.D. & Lye, S.J. (2018) Comparative  
737 analysis of gene expression in maternal peripheral blood and monocytes during  
738 spontaneous preterm labor. *American journal of obstetrics and gynecology*, **218**,  
739 345.e341-345.e330.  
740
- 741 Pringle, K., Tadros, M., Callister, R.J. & Lumbers, E. (2011a) The expression and localization of  
742 the human placental prorenin/renin-angiotensin system throughout pregnancy: Roles in  
743 trophoblast invasion and angiogenesis? *Placenta*, **32**, 956-962.  
744
- 745 Pringle, K.G., Tadros, M.A., Callister, R.J. & Lumbers, E.R. (2011b) The expression and  
746 localization of the human placental prorenin/renin-angiotensin system throughout  
747 pregnancy: roles in trophoblast invasion and angiogenesis? *Placenta*, **32**, 956-962.  
748
- 749 Qiao, J. (2020) What are the risks of COVID-19 infection in pregnant women? *Lancet (London,*  
750 *England)*, **395**, 760-762.  
751
- 752 Rasmussen, S.A., Smulian, J.C., Lednický, J.A., Wen, T.S. & Jamieson, D.J. (2020) Coronavirus  
753 Disease 2019 (COVID-19) and pregnancy: what obstetricians need to know. *American*  
754 *journal of obstetrics and gynecology*, **222**, 415-426.  
755
- 756 Redline, R.W., Faye-Petersen, O., Heller, D., Qureshi, F., Savell, V. & Vogler, C. (2003)  
757 Amniotic infection syndrome: nosology and reproducibility of placental reaction patterns.  
758 *Pediatric and developmental pathology : the official journal of the Society for Pediatric*  
759 *Pathology and the Paediatric Pathology Society*, **6**, 435-448.  
760
- 761 Romero, R., Salafia, C.M., Athanassiadis, A.P., Hanaoka, S., Mazor, M., Sepulveda, W. &  
762 Bracken, M.B. (1992) The relationship between acute inflammatory lesions of the  
763 preterm placenta and amniotic fluid microbiology. *American journal of obstetrics and*  
764 *gynecology*, **166**, 1382-1388.  
765
- 766 Salio, C., Lossi, L., Ferrini, F. & Merighi, A. (2005) Ultrastructural evidence for a pre- and  
767 postsynaptic localization of full-length trkB receptors in substantia gelatinosa (lamina II)  
768 of rat and mouse spinal cord. *The European journal of neuroscience*, **22**, 1951-1966.  
769
- 770 Schwartz, D.A. (2020) An Analysis of 38 Pregnant Women with COVID-19, Their Newborn  
771 Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus  
772 Infections and Pregnancy Outcomes. *Archives of pathology & laboratory medicine*.  
773
- 774 Shah, P.S., Diambomba, Y., Acharya, G., Morris, S.K. & Bitnun, A. (2020) Classification  
775 system and case definition for SARS-CoV-2 infection in pregnant women, fetuses, and  
776 neonates. *Acta obstetrica et gynecologica Scandinavica*, **99**, 565-568.  
777

- 778 Shynlova, O., Nadeem, L., Zhang, J., Dunk, C. & Lye, S. (2020) Myometrial activation: Novel  
779 concepts underlying labor. *Placenta*, **92**, 28-36.  
780
- 781 Silasi, M., Cardenas, I., Kwon, J.Y., Racicot, K., Aldo, P. & Mor, G. (2015) Viral infections  
782 during pregnancy. *American journal of reproductive immunology (New York, N.Y. :  
783 1989)*, **73**, 199-213.  
784
- 785 Valdés, G., Neves, L.A., Anton, L., Corthorn, J., Chacón, C., Germain, A.M., Merrill, D.C.,  
786 Ferrario, C.M., Sarao, R., Penninger, J. & Brosnihan, K.B. (2006) Distribution of  
787 angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies.  
788 *Placenta*, **27**, 200-207.  
789
- 790 Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., Godbout, K., Parsons, T.,  
791 Baronas, E., Hsieh, F., Acton, S., Patane, M., Nichols, A. & Tummino, P. (2002)  
792 Hydrolysis of biological peptides by human angiotensin-converting enzyme-related  
793 carboxypeptidase. *The Journal of biological chemistry*, **277**, 14838-14843.  
794
- 795 Wan, Y., Shang, J., Graham, R., Baric, R.S. & Li, F. (2020) Receptor Recognition by the Novel  
796 Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of  
797 SARS Coronavirus. *Journal of Virology*, **94**, e00127-00120.  
798
- 799 Wang, S., Guo, L., Chen, L., Liu, W., Cao, Y., Zhang, J. & Feng, L. (2020) A Case Report of  
800 Neonatal 2019 Coronavirus Disease in China. *Clinical Infectious Diseases*.  
801
- 802 Zamaniyan, M., Ebadi, A., Aghajanoor, S., Rahmani, Z., Haghshenas, M. & Azizi, S. (2020)  
803 Preterm delivery, maternal death, and vertical transmission in a pregnant woman with  
804 COVID-19 infection. *Prenatal diagnosis*.  
805
- 806 Zeng, H., Xu, C., Fan, J., Tang, Y., Deng, Q., Zhang, W. & Long, X. (2020) Antibodies in  
807 Infants Born to Mothers With COVID-19 Pneumonia. *Jama*, **323**, 1848-1849.  
808
- 809 Zhang, H., Penninger, J.M., Li, Y., Zhong, N. & Slutsky, A.S. (2020a) Angiotensin-converting  
810 enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential  
811 therapeutic target. *Intensive Care Med*, **46**, 586-590.  
812
- 813 Zhang, L., Jiang, Y., Wei, M., Cheng, B.H., Zhou, X.C., Li, J., Tian, J.H., Dong, L. & Hu, R.H.  
814 (2020b) [Analysis of the pregnancy outcomes in pregnant women with COVID-19 in  
815 Hubei Province]. *Zhonghua fu chan ke za zhi*, **55**, 166-171.  
816  
817  
818  
819  
820